By focusing on these high-risk but undertreated groups, our work aims to extend trial findings to routine practice and to inform strategies for improving secondary prevention and ensuring equitable access to cardioprotective therapies. GLP-1 use after MI or stroke The researchers conducted a nationwide, observational study using Czech national health registry data from 2015 to 2024 to evaluate the real-world impact of GLP-1 initiation after nonfatal MI or stroke among patients with diabetes
Taking it at night with carbohydrates may improve endurance performance, help reduce muscle damage post-workout, and help avoid an upset stomach
Switching between these medications is clinically common and can be done safely under medical supervision
Available data suggest the incidence may be somewhat higher at greater doses and during periods of dose escalation, though precise figures by dose group and comparison with placebo rates should be sought from the published trial data directly
As strength and power decline with age, patients and providers fear going on GLP-1s as trading obesity risk for early frailty
When the dose goes up little by little, people can better see how their body responds and find the right maintenance dose without putting too much pressure on the system